NCT02537405View on ClinicalTrials.gov

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Embolism, Atrial Fibrillation and Venous Thrombosis
Interventions
DRUG

Rivaroxaban (BAY 59-7939)

Rivaroxaban granule 10mg for one day

DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Rivaroxaban tablet 10mg for one day

Trial Locations (1)

861-4157

Kumamoto

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY